Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced it will present posters at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference from May 28-31, 2024, in Miami Beach, Florida.
The presentations will focus on fasedienol (PH94B) for social anxiety disorder (SAD) and itruvone (PH10) for major depressive disorder (MDD). The fasedienol poster, titled 'Results from the PALISADE-2 Phase 3 Trial,' will be presented on May 29, 2024, at 11:15 a.m. ET. The itruvone poster, titled 'Brain and Peripheral Tissue Distribution of Intranasal Radiolabeled Itruvone (PH10) in Laboratory Rats,' will also be presented on May 29, 2024, at 11:15 a.m. ET.
Both posters will be available on Vistagen's website from June 3, 2024.
- Vistagen will present at a major scientific conference, enhancing its visibility in the medical community.
- Focus on two investigational therapies, fasedienol and itruvone, indicates progress in Phase 3 and Phase 2 trials respectively.
- Fasedienol has reached Phase 3 trials, suggesting advanced development and potential market readiness.
- The presentation at ASCP could attract attention from potential investors or partners.
- No concrete data or results from the trials were provided in the press release.
- The company has not specified any timeline for potential market approval or commercialization.
- Reliance on future data availability might indicate current uncertainty about trial outcomes.
- Focus on investigational candidates means revenue generation is likely not imminent.
Poster Presentation
Date: Wednesday, May 29, 2024, 11:15 a.m. Eastern Time
Title: Fasedienol (PH94B) Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD):
Results from the PALISADE-2 Phase 3 Trial
Authors: Michael R. Liebowitz, MD; Ester Salmán, MPH; Rita Hanover, PhD; Brittany Reed, PA; Ross A. Baker, PhD; and Louis Monti, MD, PhD
Poster Number: W96
Poster Presentation
Date: Wednesday, May 29, 2024, 11:15 a.m. Eastern Time
Title: Brain and Peripheral Tissue Distribution of Intranasal Radiolabeled Itruvone (PH10) in Laboratory Rats
Authors: Jo Cato PhD; Ross A. Baker, PhD; and Louis Monti, MD, PhD
Poster Number: W78
The posters will be available on the Publications page of Vistagen’s website on Monday, June 3, 2024.
About Fasedienol Nasal Spray
Vistagen’s fasedienol (PH94B) is a first-in-class, synthetic rapid-onset investigational pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). Fasedienol’s novel neurocircuitry-focused proposed mechanism of action (MOA) is differentiated from the SSRIs and SNRI currently approved for the treatment of SAD, as well as all benzodiazepines and other medications prescribed off label for SAD. There is no FDA-approved acute treatment of SAD. When administered intranasally in microgram-level doses, fasedienol activates receptors in peripheral nasal chemosensory neurons that, in turn, activate olfactory system neurocircuitry and limbic amygdala neurocircuits involved in the pathophysiology of SAD, and potentially other acute anxiety and mood disorders. Fasedienol is pharmacologically active without requiring systemic absorption and distribution, or binding to neurons in the brain. Given fasedienol’s rapid-onset MOA and patient-tailored as-needed administration, it has the potential to become the first FDA-approved acute treatment for SAD, which is the focus of Vistagen’s ongoing registration-directed PALISADE Phase 3 program. The
About Itruvone Nasal Spray
Itruvone (PH10) is a synthetic rapid-onset investigational pherine nasal spray in Phase 2 development for the treatment of moderate to severe major depressive disorder (MDD). Itruvone’s proposed mechanism of action (MOA) is fundamentally differentiated from the MOA of all currently approved treatments for MDD. Administered intranasally at microgram-level doses, itruvone’s MOA involves the regulation of olfactory-to-amygdala neural circuits believed to increase the activity of the limbic-hypothalamic sympathetic nervous system and increase the release of catecholamines. Unlike all currently approved depression therapies, itruvone does not require systemic absorption and distribution or binding to neurons in the brain to produce antidepressant effects without the side effects and safety concerns that may be associated with current antidepressant therapies. The
About Vistagen
Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen (the Company) and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Among other things, there can be no guarantee that any of the Company’s drug candidates will successfully complete ongoing or future clinical trials, receive regulatory approval or be commercially successful. These risks and others are more fully discussed in the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 31, 2023, and in the Company’s Quarterly Report on Form 10-Q for the period ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523119550/en/
Investors:
Mark McPartland
Vistagen Therapeutics
markmcp@vistagen.com
Media:
Caren Scannell
Vistagen Therapeutics
cscannell@vistagen.com
Source: Vistagen
FAQ
What will Vistagen present at the 2024 ASCP Conference?
When and where is the 2024 ASCP Conference?
What is the significance of Vistagen's fasedienol (PH94B)?
What is itruvone (PH10) being developed for?
When will Vistagen's posters be available online?
What is the stock symbol for Vistagen?
